Search Results - "Escherich, G."

RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia by Jerchel, I S, Hoogkamer, A Q, Ariës, I M, Steeghs, E M P, Boer, J M, Besselink, N J M, Boeree, A, van de Ven, C, de Groot-Kruseman, H A, de Haas, V, Horstmann, M A, Escherich, G, Zwaan, C M, Cuppen, E, Koudijs, M J, Pieters, R, den Boer, M L

“…RAS pathway mutations have been linked to relapse and chemotherapy resistance in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However,…”
Get full text

EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion by Ariës, I M, Jerchel, I S, van den Dungen, R E S R, van den Berk, L C J, Boer, J M, Horstmann, M A, Escherich, G, Pieters, R, den Boer, M L

“…Still 20% of pediatric acute lymphoblastic leukemia (ALL) patients relapse on or after current treatment strategies. Treatment failure is associated with…”
Get full text

Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97 by Escherich, G, Horstmann, M A, Zimmermann, M, Janka-Schaub, G E

“…In this study, the long-term outcome of 1818 patients treated in five consecutive clinical trials (the cooperative study group for childhood acute…”
Get full text

Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol by Stutterheim, J., de Lorenzo, P., van der Sluis, I.M., Alten, J., Ancliffe, P., Attarbaschi, A., Aversa, L., Boer, J.M., Biondi, A., Brethon, B., Diaz, P., Cazzaniga, G., Escherich, G., Ferster, A., Kotecha, R.S., Lausen, B., Leung, Alex WK, Locatelli, F., Silverman, L., Stary, J., Szczepanski, T., van der Velden, V.H.J., Vora, A., Zuna, J., Schrappe, M., Valsecchi, M.G., Pieters, R.

“…The outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior…”
Get full text

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol by Driessen, E M C, de Lorenzo, P, Campbell, M, Felice, M, Ferster, A, Hann, I, Vora, A, Hovi, L, Escherich, G, Li, C K, Mann, G, Leblanc, T, Locatelli, F, Biondi, A, Rubnitz, J, Schrappe, M, Silverman, L, Stary, J, Suppiah, R, Szczepanski, T, Valsecchi, M, Pieters, R

Get full text

Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment by Eckert, C, Hagedorn, N, Sramkova, L, Mann, G, Panzer-Grümayer, R, Peters, C, Bourquin, J-P, Klingebiel, T, Borkhardt, A, Cario, G, Alten, J, Escherich, G, Astrahantseff, K, Seeger, K, Henze, G, von Stackelberg, A

“…The prognosis for children with high-risk relapsed acute lymphoblastic leukemia (ALL) is poor. Here, we assessed the prognostic importance of response during…”
Get full text

Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors - presentation of the CARE for CAYA-Program study protocol and associated literature review by Salchow, J, Mann, J, Koch, B, von Grundherr, J, Jensen, W, Elmers, S, Straub, L A, Vettorazzi, E, Escherich, G, Rutkowski, S, Dwinger, S, Bergelt, C, Sokalska-Duhme, M, Bielack, S, Calaminus, G, Baust, K, Classen, C F, Rössig, C, Faber, J, Faller, H, Hilgendorf, I, Gebauer, J, Langer, T, Metzler, M, Schuster, S, Niemeyer, C, Puzik, A, Reinhardt, D, Dirksen, U, Sander, A, Köhler, M, Habermann, J K, Bokemeyer, C, Stein, A

“…Improved, multimodal treatment strategies have been shown to increase cure rates in cancer patients. Those who survive cancer as a child, adolescent or young…”
Get full text

Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia by Löbel, U., Trah, J., Escherich, G.

“…Systemic and intrathecal methotrexate is widely used in treatment protocols for childhood acute lymphoblastic leukemia. Its side effects vary in…”
Get full text

Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004 by Rasche, M, von Neuhoff, C, Dworzak, M, Bourquin, J-P, Bradtke, J, Göhring, G, Escherich, G, Fleischhack, G, Graf, N, Gruhn, B, Haas, O A, Klingebiel, T, Kremens, B, Lehrnbecher, T, von Stackelberg, A, Tchinda, J, Zemanova, Z, Thiede, C, von Neuhoff, N, Zimmermann, M, Creutzig, U, Reinhardt, D

“…We conducted a cytogenetic analysis of 642 children with de novo acute myeloid leukemia (AML) treated on the AML-Berlin-Frankfurt-Münster (BFM) 04 protocol to…”
Get full text

Improved nutrition in adolescents and young adults after childhood cancer - INAYA study by Quidde, J, von Grundherr, J, Koch, B, Bokemeyer, C, Escherich, G, Valentini, L, Buchholz, D, Schilling, G, Stein, A

“…Multimodality treatment improves the chance of survival but increases the risk for long-term side effects in young cancer survivors, so-called" Adolescents and…”
Get full text

Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia by Escherich, G, Richards, S, Stork, L C, Vora, A J

“…Mercaptopurine has been used in continuing treatment of childhood acute lymphoblastic leukaemia since the mid 1950s. Recent advances in the understanding of…”
Get full text

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol by Driessen, E M C, de Lorenzo, P, Campbell, M, Felice, M, Ferster, A, Hann, I, Vora, A, Hovi, L, Escherich, G, Li, C K, Mann, G, Leblanc, T, Locatelli, F, Biondi, A, Rubnitz, J, Schrappe, M, Silverman, L, Stary, J, Suppiah, R, Szczepanski, T, Valsecchi, M, Pieters, R

“…This corrects the article DOI: 10.1038/leu.2015.246…”
Get full text

S108: PEDIATRIC T‐ ALL RELAPSE: CONSTITUTIONAL CANCER PREDISPOSITION AND HYPERMUTATATOR PHENOTYPES by Richter‐Pechanska, P., Kunz, J., Rausch, T., Erarslan‐Uysal, B., Bornhauser, B., Frismantas, V., Assenov, Y., Zimmermann, M., Happich, M., Knebel‐Doeberitz, C., Neuhoff, N., Koehler, R., Stanulla, M., Schrappe, M., Cario, G., Escherich, G., Kischner‐Schwabe, R., Eckert, C., Avigad, S., Pfister, S., Muckenthaler, M., Bourquin, J.‐P., Korbel, J., Kulozik, A.

Get full text

Significantly increased CD70 up regulation on TEL-AML positive B cell precursor acute lymphoblastic leukemia cells following CD40 stimulation by Troeger, A, Glouchkova, L, Ackermann, B, Escherich, G, Hanenberg, H, Janka, G, Roettgers, S, Göbel, U, Dilloo, D

“…TEL-AML the most common genetic alteration in childhood precursor B acute lymphoblastic leukemia (BCP-ALL) is associated with a favorable prognosis. We studied…”
Get more information

The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97) by ESCHERICH, Gabriele, TRÖGER, Anja, PIETERS, Rob, DEN BOER, Monique L, HORSTMANN, Martin, JANKA, Gritta E, GÖBEL, Ulrich, GRAUBNER, Ulrike, PEKRUN, Arnulf, JORCH, Norbert, KASPERS, Gjl, ZIMMERMANN, Martin, ZUR STADT, Udo, KAZEMIER, Karin

“…In a study of childhood acute lymphoblastic leukemia (CoALL 06-97 study), the in vitro sensitivity of the patients' cells to prednisolone, vincristine and…”
Get full text

Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia by van der Veer, A, van der Velden, V H J, Willemse, M E, Hoogeveen, P G, Petricoin, E F, Beverloo, H B, Escherich, G, Horstmann, M A, Pieters, R, den Boer, M L

Get full text

Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97 by Vieira Pinheiro, J P, Wenner, K, Escherich, G, Lanvers-Kaminsky, C, Würthwein, G, Janka-Schaub, G, Boos, J

“…Pharmacological surrogate parameters are considered a useful tool in estimating the treatment intensity of asparaginase (ASNase) preparations. When a pegylated…”
Get full text

Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia by Escherich, G, Göbel, U, Jorch, N, Spaar, H J, Janka-Schaub, G E

“…Daunorubicin (DNR) is one of the most important drugs in treatment of acute lymphoblastic leukemia (ALL). Prolonged infusions of anthracyclines are less…”
Get more information

Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia by Tröger, A, Siepermann, M, Mahotka, C, Wethkamp, N, Bülle, H, Laws, H-J, Escherich, G, Janka-Schaub, G, Göbel, U, Dilloo, D

“…Survivin, a member of the inhibitor of apoptosis protein (IAP) family is transiently expressed at low levels during normal hematopoesis but profoundly…”
Get more information

Reduced expression and defective modulation of TNF receptor/ligand family molecules on proB-ALL blasts by Troeger, A, Glouchkova, L, Escherich, G, Siepermann, M, Hanenberg, H, Janka-Schaub, G, Göbel, U, Ackermann, B, Dilloo, D

“…There is a subgroup of pediatric patients with an immature immunophenotype of proB-ALL that still poses a therapeutic challenge, even if the overall prognosis…”
Get more information